secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001937653-23-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports FY 2022 net income $124.3M vs loss; $492.2M cash; Jazz deal $375M upfront
--------------------------------------------------------------------------------

- Revenue $412.5M (FY22) vs $26.7M (FY21) driven by $375M upfront from Jazz collaboration.
- Net income $124.3M ($1.90 diluted EPS) vs net loss $211.8M in prior year; cash $492.2M through 2026.
- Jazz deal total potential $1.76B; tiered royalties 10-20% on Jazz net sales if approved.
- Zanidatamab: Phase 2 BTC cORR 41.3%, median DOR 12.9 months; GEA 84% OS at 18mo.
- 2023 net cash burn guidance $90-120M incl. $15M capex; zanidatamab zovodotin Phase 2 studies start 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/0001937653-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/zyme-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001937653-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer